Produkty
Producenci
Amphomycin
Opis
Produkt przeznaczony wyłącznie do badań. Nie nadaje się do spożycia.
Amphomycin is a lipopeptide antibiotic produced by Streptomycetes and Actinoplanes, initially reported by researchers at Bristol-Myers in 1953 from Streptomyces canus. Amphomycin was marketed as a complex of closely related analogues in the 1950s and 1960s. Structure elucidation was not completed until 2000. Amphomycin is closely related to a number of "lost" antibiotics, aspartocin, crystallomycin, glumamycin, friulimicin, laspartocin, tsushimycin and zaomycin. Interest in amphomycin was re-awakened with the discovery of friulimicin activity against antibiotic resistant strains.
Amphomycin is soluble in ethanol, methanol, DMF and DMSO.
Cas Number: 1402-82-0
Molecular Formula: C58H91N13O20
Molecular Weight: 1290.4
Mechanism of Action: Amphomycin inhibits peptidoglycan synthesis and blocks cell wall development.
Storage Conditions: -20°C
Purity Level: >95% by HPLC
References: Amphomycin. A new antibiotic. Heineman B. et al. Antibiot. Chemother. 1953, 3, 1239.
Studies on bacterial cell wall inhibitors. II. Inhibition of peptidoglycan synthesis in vivo and in vitro by amphomycin. Tanaka H. et al. Biochim. Biophys. Acta 1977, 497, 633.
Friulimicins: Novel lipopeptide antibiotics with peptidoglycan synthesis inhibiting activity from Actinoplanes friuliensis sp. nov. I. Taxonomic studies of the producing microorganism and fermentation. Aretz W. et al. J. Antibiot. 2000, 53, 807.
Friulimicins: Novel lipopeptide antibiotics with peptidoglycan synthesis inhibiting activity from Actinoplanes friuliensis sp. nov. II. Isolation and structural characterization. Vertesy L. et al. J. Antibiot. 2000, 53, 816.
Dane techniczne
| Opakowanie | 5 mg |